China-UK nanotech joint venture signed

27 November 2006

The China National Academy of Nanotechnology & Engineering and the UK's Institute of Pharmaceutical Innovation at the University of Bradford have launched a joint initiative to pioneer novel technology to improve medicines, using nanotechnology techniques.

Paul Thorning, the IPI's director, said: "this has been a major breakthrough for us. CNANE is a world-class organization and has leading research capabilities in nanotechnology. This partnership will further strengthen our research in this field and provides us with a link to one of the fastest-growing pharmaceutical markets in the world."

The CNANE is a multi-disciplinary research center that is co-funded by the Chinese Academy of Science, Beijing University and Tsinghua University. The Academy's vice president said: "we see international collaboration as the most important element for the development of science and technology. The development with the IPI greatly strengthens our scientific capability and will accelerate the pace of our research development."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight